Nativita is preparing to approach a pharmaceutical market of Hungary.
JLLC “Nativita” and Hungarian company Pharma Gap Kft have signed an agreement of cooperation intent in Budapest on July 20.
As Vladimir Sychov commented on, Chief Operating Officer of our company, “we have concluded a memorandum of intent which would give us the opportunity to start the dossier evaluation for the registration of our medicines in Hungary in conjunction with Slovakia. Now we are preparing the ground for speedy launch to the markets of Central and Eastern European Countries”.
Pictured (L to R): Doctor Gabor Gábor Metzger, Managing Director of the company Onkogen (Hungary), Vladimir Sychov, Chief Operating Officer of JLCC “Nativita”, Alexandr Ponomarev, Ambassador Extraordinary and Plenipotentiary of Belarus in Hungary and in the Republic of Croatia (combined duties)
“In short-range plans of the company is the registration and the distribution of life-saving medicines, originating in Belarus, on the territory of Hungary and other countries. There are pharmaceutical products applied in treating of cancer diseases, as well as cytokine storm in infectious disease, caused by COVID-19”, was it noted in the Embassy of Belarus in Hungary where the conclusion of a document was held.